Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Update on Intravenous DMT Study
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(127)
•••
Post by SkywalkerofLukeon May 15, 2023 4:44pm
159 Views
Post# 35449037

Update on Intravenous DMT Study

Update on Intravenous DMT Study

The stroke treatment market is est. to reach value of $15B by 2027 & the global traumatic brain injury market is projected to grow from 3.1B to 4.5B by 2026. AGN.c AGNPF is working to address these with intravenous DMT.


They were recently approved to move forward with the final cohort in their Phase 1 clinical study, where they’re testing the safety, tolerability, and pharmacokinetics of intravenous DMT for the potential treatment of stroke and traumatic brain injury.


CEO stated once they finalize the correct dose and optimum exposure period the quicker they can move to phase 2.


https://twitter.com/AlgernonPharma/status/1656010922786267137

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities